RT Journal Article SR Electronic T1 A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV-2 proliferation: in vitro evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.11.20248947 DO 10.1101/2021.01.11.20248947 A1 Christos Lionis A1 Ioannis Karakasiliotis A1 Elena Petelos A1 Manolis Linardakis A1 Athanasios Diamantakis A1 Emmanouil Symvoulakis A1 Maria Panopoulou A1 Marilena Kampa A1 Stergios A. Pirintsos A1 George Sourvinos A1 Elias Castanas YR 2021 UL http://medrxiv.org/content/early/2021/01/15/2021.01.11.20248947.abstract AB The need for therapeutic regimens for the non-critically ill patients of the COVID-19 pandemic remains unmet. In this line, repurposing existing drugs, against known or predicted SARS-CoV-2 protein actions, has been advanced, while natural products have also been tested. Previous work has shown that a Cretan Aromatic Plant (Thymbra capitata (L.) Cav., Salvia fruticosa Mill. and Origanum dictamnus L.) essential oil mixture (CAPeo) has a remarkable in vitro antiviral activity against Influenza A & B and Rhinovirus 14 strains, decreasing the symptoms of upper respiratory tract infections, while proven safe in experimental animals and humans. Here, we tested CAPeo in VERO cells infected with SASR-CoV-2. We report that this mixture, at similar concentrations as those previously reported, exhibits a remarkable antiviral activity. Administration of 1 ml of a 1.5% CAPeo in olive oil, in a Proof-of-Concept intervention study in SARS-CoV-2-positive, exhibiting mild COVID-19 symptoms, humans resulted in a significant amelioration of general and local symptoms of the disease. We conclude that CAPeo may be a valuable addition for the prevention and/or treatment of mild COVID-19 ambulatory patients, pending a confirmation through a prospective randomized controlled trial in humans (NCT04705753).Competing Interest StatementSAP, CL and EC are inventors in patents CN102762218, EP2482831 and WO2011045557, with priority numbers WO2010GB01836 20100929 and GB20090017086 20090929, related to the antiviral activity of the CAPeo.Clinical TrialNCT04705753Funding StatementThe clinical study, for which the Ethics Approval was given was exclusively supported by Clinic of Social and Family Medicine, University of Crete, funds. The work was also partially supported by Olvos Science SA and a grant from Galenica SA to IK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Crete Bioethics Committee (No 78/01.04.2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript